Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

58.03
-0.3050-0.52%
Volume:434.57K
Turnover:25.14M
Market Cap:14.38B
PE:18.25
High:58.33
Open:58.33
Low:57.45
Close:58.33
52wk High:59.72
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.35
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.80
PE(LYR):20.87

Loading ...

Exelixis Inc : UBS Raises Target Price to $52 from $43

THOMSON REUTERS
·
Jul 02

Exelixis is Maintained at Neutral by UBS

Dow Jones
·
Jul 02

Exelixis Price Target Maintained with a $56.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 02

Apollo, Exelixis, Devon, Qualcomm, Oklo Trending With Analysts

TIPRANKS
·
Jun 27

Is Exelixis (EXEL) Fully Valued On Its STELLAR 303 Trial Update?

Simply Wall St.
·
Jun 27

Exelixis Cut to Hold from Buy by Truist Securities

Dow Jones
·
Jun 25

Exelixis Inc : Truist Securities Cuts to Hold from Buy; Raises Target Price to $54 from $51

THOMSON REUTERS
·
Jun 25

Exelixis assumed with Hold from Buy at Truist

TIPRANKS
·
Jun 25

U.S. Research Roundup-caseys General Stores, Micron Technology, SAP

Reuters
·
Jun 25

Exelixis is Maintained at Market Outperform by Citizens

Dow Jones
·
Jun 24

Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price

TIPRANKS
·
Jun 23

Exelixis announces results from final analysis of phase 3 STELLAR-303 trial

TIPRANKS
·
Jun 22

Exelixis says STELLAR-303 trial misses statistical significance for survival in metastatic colorectal cancer non-liver subgroup

Reuters
·
Jun 22

Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination With an Immune Checkpoint Inhibitor in Patients With Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jun 22

Exelixis - No New Safety Signals Identified for Zanzalintinib Plus Atezolizumab in Nlm Subgroup

THOMSON REUTERS
·
Jun 22

How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO

Simply Wall St.
·
Jun 17

How Broad CABOMETYX PFS Benefit At Exelixis (EXEL) Has Changed Its Investment Story

Simply Wall St.
·
Jun 07

Exelixis director Jack L. Wyszomierski sells 3,925 common shares for $198,408.75

Reuters
·
Jun 04

Exelixis director Sue Gail Eckhardt sells 9,812 shares for $491,974.68

Reuters
·
Jun 04

Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial

TIPRANKS
·
May 31